0
Home
News
Directory
E-newsletter
Magazine
Events
Data
AgReport
Subscribe
Bayer launches ILeVO, the first soybean seed treatment registered for Sudden Death Syndrome in Canada
Nov. 15, 2016
Bayer CropScience Canada
CanadaFollow
CanadaBayer announces the launch of ILeVO™ seed treatment, the first soybean seed treatment registered for Sudden Death Syndrome (SDS) in Canada.
SDS is caused by Fusarium virguliforme. This fungal pathogen overwinters on crop residue and is occurring more frequently in fields across Ontario. Difficult to identify and often misdiagnosed, the disease results in average annual yield loss of about 20 per cent, but can cause losses of up to 60 per cent in a growing season. To date, there have been no seed treatment solutions available for SDS in Canada.
“ILeVO gives growers a way to protect against SDS, a yield robbing pest,” says David Kikkert, crop & campaign marketing manager, soybeans & pulses at Bayer. “As the first seed treatment solution available for SDS in Canada, it’s a revolutionary new way to help protect soybean crops and the growers’ bottom line.”
ILeVO has activity on the Fusarium virguliforme fungus. The effectiveness of the product has been demonstrated through field trials in the US and Canada over the past five years, including third-party trials with OMAFRA and the University of Guelph.
“With the increased cases of SDS in Ontario putting pressure on growers, it’s important to have tools ready to help protect their fields,” said Albert Tenuta, Field Crop Pathologist at OMAFRA. “Growers are continuing to plant in earlier, wetter conditions and reducing the risk of infection at planting will help maximize yields.”
A feature unique to ILeVO which signals a successful application is the “halo effect” which is often visible on the edges of the cotyledons of a treated plant. “ILeVo helps growers protect their soybean fields and helps with the production of higher yielding, healthier soybean plants.” continues Kikkert.
Source: Bayer CropScience Canada
More from AgroNews
Change
Hot TopicSubscribe
| Subscribe Email: | * | |
| Name: | ||
| Mobile Number: | ||
Comment
0/1200
NEWSLETTER